SlideShare une entreprise Scribd logo
1  sur  19
Télécharger pour lire hors ligne
1
2Q11 Earnings Release
         August, 11th, 2011




                              2
Highlights in the Period


• Net income rose by 333.6% quarter-over-quarter and totaled R$ 9.5 million, with a 1.4% net margin;


• Consolidated gross revenues grew 7.5% year-over-year, totaling R$ 779.4 million;


• Highlight for the health and beauty category, whose sales increased for the sixth quarter in a row. There was a steep year-
over-year increase of 87.3%;


• The positive operating cash flow amounted to R$ 50.0 million in 2Q11, or 7.6% of the net operating revenue;


• There was 5.8-day reduction in the cash cycle. This decrease resulted in a drop in working capital of about R$ 45.4
million;


• Operating (administrative, selling and logistics) expenses fell by 1.4 percentage point year-over-year and totaled 7.5% of
the net operating revenue;


• Sales through electronic orders hit a record high and accounted for 68.6% of total sales in 2Q11.



                                                                                                                                3   3
Gross Revenues Evolution
                (R$ Million)




                  778.8            779.4


724.7




2Q10              1Q11             2Q11




                                           4   4
Gross Revenues Breakdown


(R$ Million)                    2Q11    2Q10    Chg. %   1Q11    Chg. %

Branded                         512.2   477.5    7.3%    507.1   1.0%
Generic                          45.7    50.3   -9.1%     54.5   -16.1%
OTC                             141.3   143.8   -1.7%    148.7   -4.9%
Health and Beauty Products       53.9    28.8   87.3%     47.6   13.1%
Hospitals + Vaccines             26.3    24.3    7.9%     21.0   25.3%

Total                           779.4   724.7    7.5%    778.8   0.1%




                                                                          5   5
Market Share Evolution (%)



                          11.5    11.7
                                             10.9*
                                                         10.2*
       9.6                                                            9.5*   9.9*
                                                                                            9.0*




      2006                2007    2008       2009        2010         2Q10   1Q11          2Q11

*Excluding the similar’s effect                                                Source: IMS and Profarma




                                                                                                          6   6
Gross Profit and Revenues from Services to Suppliers
                 (R$ million and as % Net Revenues)




   12.3%
                                                        10.7%
                                9.6%



    25.1
                                                         27.4
                                24.0



    49.7
                                39.1                     42.9




    2Q10                       1Q11                     2Q11

Gross Profit   Revenues from Services to Suppliers    Gross Profit Margin (%)




                                                                                7   7
Operating Expenses
       (R$ million and as % Net Revenues)



8.9%
                    7.7%                    7.5%


53.8
                     50.7                   49.5




2Q10                1Q11                    2Q11




                                                   8   8
Ebitda and Ebitda Margin
       (R$ million and as % Net Revenues)




3.6%                                        3.2%

                    1.7%



21.8
                                            20.7




                     10.9




2Q10                 1Q11                   2Q11




                                                   9   9
Net Financial Expenses
       (R$ million and as % Net Revenues)



1.9%
                                            1.3%
                     1.1%


11.8


                                            8.8

                      7.2




2Q10                1Q11                    2Q11




                                                   10 10
Net Profit
       (R$ million and as % Net Revenues)




1.9%
                                            1.4%

                     0.3%

11.4

                                            9.5




                      2.2




2Q10                1Q11                    2Q11




                                                   11 11
CASH FLOW

(R$ Million)                                             2Q11     2Q10      Chg. %   1Q11     Chg. %

Cash Flow Generated / (Used) in Operating Activities     50,0      46,8     6,9%     (80,2)      -
  Internal Cash Generation                               19,8      17,6     12,7%    10,4     90,6%
 Operating Assets Variation                              30,2      29,2     3,5%     (90,6)      -
     Trade Accounts Receivable                           37,3      28,3     31,7%    22,9     62,6%
     Inventories                                         46,3      92,4     -50,0%   (30,8)      -
     Suppliers                                           (48,7)   (105,2)   53,7%    (74,7)   34,8%
     Other Items                                         (4,6)     13,7       -      (8,1)    42,9%

Cash Flow (Used) in Investing Activities                 (1,8)     (1,9)    3,3%     (1,3)    -43,2%

Cash Flow Generated / (Used) by Financing Activities     (51,0)   (53,7)    5,1%     81,1        -

Net Increase / (Decrease) in Cash                        (2,8)     (8,8)    68,5%    (0,4)    -659,2%




                                                                                                        12 12
Cycle IFRS Basis

                                        2Q10 1Q11 2Q11
  Cash Cycle (Days) *                    66.3    64.5   60.4

  Accounts Receivable (1)                42.2    43.9   39.4
  Inventories (2)                        48.8    59.3   53.1
  Accounts Payable (3)                   24.8    38.7   32.0

* Average
(1)   Average of Gross Revenues in the Quarter
(2)   Average of COGS in the Quarter
(3)   Average of COGS in the Quarter




                                                               13 13
Indebtedness: Net Debt and Net Debt / Ebitda*
                                        (R$ million)




                                           2.7x                 2.2x
                     1.4x



                                          194.8

                                                               157.1
                    132.5




                    2Q10                  1Q11                 2Q11

* Ebitda = Accumulated last 12 months




                                                                       14 14
Capex
       (R$ million and % as Net Revenues)




0.3%                 0.2%                   0.3%




1.9                                         1.9
                      1.3




2Q10                 1Q11                   2Q11




                                                   15 15
Operating Indicators

                Service Level                                         Logistics E.P.M.
        (Units served/ Units requested)                               (Errors per Million)



89.6%               89.5%                                                                    337.0
                                          88.6%




                                                                          144.0
                                                              121.0




2Q10                1Q11                  2Q11                2Q10         1Q11              2Q11




                                                                                                     16 16
Profarma vs Ibovespa - % (2Q11)

115




110




105




100

                                                                                                   97
 95



                                                                                                   91
 90




 85
  31-Mar-11   15-Apr-11   30-Apr-11              15-May-11          30-May-11   14-Jun-11   29-Jun-11



                                      Ibovespa               Profarma




                                                                                                        17 17
Analyst Coverage

Company          Analyst                           Telephone           E-mail


                 Javier Martinez de Olcoz Cerdan   (1 212) 761-4542    javier.martinez.olcoz@morganstanley.com
Morgan Stanley
                 Clarissa Berman                   (55 11) 3048-6214   clarissa.berman@morganstanley.com


Merrill Lynch    Alexandre Pizano                  (55 11) 2188-4024   alexandre.pizano@baml.com

Credit Suisse    Marcel Moraes                     (55 11) 3841-6302   marcel.moraes@credit-suisse.com


                 Juliana Rozenbaum                 (55 11) 3073-3035   juliana.rozenbaum@itausecurities.com
Itaú BBA
                 Marcio Osako                      (55 11) 3073-3040   marcio.osako@itausecurities.com


Banco Fator      Iago Whately                      (55 11) 3049-9480   iwhately@bancofator.com.br

Raymond James    Guilherme Assis                   (55 11) 3513-8706   guilherme.assis@raymondjames.com

BTG Pactual      João Carlos dos Santos            (55 11) 3383-2384   joaocarlos.santos@btgpactual.com




                                                                                                                 18 18
19

Contenu connexe

Tendances

Earnings Release 2 Q07
Earnings Release 2 Q07Earnings Release 2 Q07
Earnings Release 2 Q07Profarma
 
Earnings Release 3 Q07
Earnings Release 3 Q07Earnings Release 3 Q07
Earnings Release 3 Q07Profarma
 
Earnings Release 1 Q07
Earnings Release 1 Q07Earnings Release 1 Q07
Earnings Release 1 Q07Profarma
 
Profarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 EngProfarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 Engprofarma1
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma
 
Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationProfarma
 
Paragon Shipping Q4 2012 results presentation
Paragon Shipping Q4 2012 results presentationParagon Shipping Q4 2012 results presentation
Paragon Shipping Q4 2012 results presentationTradeWindsnews
 
Wessanen q3 2012 press release
Wessanen q3 2012 press releaseWessanen q3 2012 press release
Wessanen q3 2012 press releaseKlaus Arntz
 
Presentation 1Q12 | Locamerica
Presentation 1Q12 | LocamericaPresentation 1Q12 | Locamerica
Presentation 1Q12 | Locamericalocamerica
 
4 q11 presentation results
4 q11 presentation results4 q11 presentation results
4 q11 presentation resultsrimagazineluiza
 
raytheon Q4 Earnings Presentation
raytheon Q4 Earnings Presentationraytheon Q4 Earnings Presentation
raytheon Q4 Earnings Presentationfinance12
 

Tendances (14)

Apresentacao Call Result 1 T08 Eng Final
Apresentacao Call Result 1 T08 Eng FinalApresentacao Call Result 1 T08 Eng Final
Apresentacao Call Result 1 T08 Eng Final
 
Earnings Release 2 Q07
Earnings Release 2 Q07Earnings Release 2 Q07
Earnings Release 2 Q07
 
Earnings Release 3 Q07
Earnings Release 3 Q07Earnings Release 3 Q07
Earnings Release 3 Q07
 
Earnings Release 1 Q07
Earnings Release 1 Q07Earnings Release 1 Q07
Earnings Release 1 Q07
 
Profarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 EngProfarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 Eng
 
Investors' meeting 2 q08 results
Investors' meeting   2 q08 resultsInvestors' meeting   2 q08 results
Investors' meeting 2 q08 results
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 final
 
Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 Presentation
 
Paragon Shipping Q4 2012 results presentation
Paragon Shipping Q4 2012 results presentationParagon Shipping Q4 2012 results presentation
Paragon Shipping Q4 2012 results presentation
 
Wessanen q3 2012 press release
Wessanen q3 2012 press releaseWessanen q3 2012 press release
Wessanen q3 2012 press release
 
Presentation 1Q12 | Locamerica
Presentation 1Q12 | LocamericaPresentation 1Q12 | Locamerica
Presentation 1Q12 | Locamerica
 
FY 2011 IFRS Results
FY 2011 IFRS ResultsFY 2011 IFRS Results
FY 2011 IFRS Results
 
4 q11 presentation results
4 q11 presentation results4 q11 presentation results
4 q11 presentation results
 
raytheon Q4 Earnings Presentation
raytheon Q4 Earnings Presentationraytheon Q4 Earnings Presentation
raytheon Q4 Earnings Presentation
 

En vedette

Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vfProfarma
 
Apimec 1T14
Apimec 1T14Apimec 1T14
Apimec 1T14Profarma
 
Teleconferência 4T13 e ano 2013
Teleconferência 4T13 e ano 2013Teleconferência 4T13 e ano 2013
Teleconferência 4T13 e ano 2013Profarma
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationProfarma
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationProfarma
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationProfarma
 
Conference Call 3Q14
Conference Call 3Q14Conference Call 3Q14
Conference Call 3Q14Profarma
 
Profarma Apresentação 3Q10
Profarma Apresentação 3Q10Profarma Apresentação 3Q10
Profarma Apresentação 3Q10Profarma
 
Earnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationEarnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationProfarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationProfarma
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationProfarma
 
Apresentação pt_1t14
Apresentação pt_1t14Apresentação pt_1t14
Apresentação pt_1t14Profarma
 
Profarma apimec
Profarma apimecProfarma apimec
Profarma apimecProfarma
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16Profarma
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16Profarma
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma
 

En vedette (18)

Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vf
 
Apimec 1T14
Apimec 1T14Apimec 1T14
Apimec 1T14
 
Teleconferência 4T13 e ano 2013
Teleconferência 4T13 e ano 2013Teleconferência 4T13 e ano 2013
Teleconferência 4T13 e ano 2013
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 Presentation
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 Presentation
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Conference Call 3Q14
Conference Call 3Q14Conference Call 3Q14
Conference Call 3Q14
 
Profarma Apresentação 3Q10
Profarma Apresentação 3Q10Profarma Apresentação 3Q10
Profarma Apresentação 3Q10
 
Earnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationEarnings Release 4Q08 Presentation
Earnings Release 4Q08 Presentation
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
 
Apresentação pt_1t14
Apresentação pt_1t14Apresentação pt_1t14
Apresentação pt_1t14
 
Profarma apimec
Profarma apimecProfarma apimec
Profarma apimec
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain Acquisition
 

Similaire à Profarma apresentação 2 q11

Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12Profarma
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Engprofarma1
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12Profarma
 
Earnings Release 2Q09 Presentation
Earnings Release 2Q09 PresentationEarnings Release 2Q09 Presentation
Earnings Release 2Q09 PresentationProfarma
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationProfarma
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10Profarma
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10Profarma
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationProfarma
 
arnings Release 2Q07 Presentation
arnings Release 2Q07 Presentationarnings Release 2Q07 Presentation
arnings Release 2Q07 PresentationProfarma
 
Earnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationEarnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationProfarma
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07Profarma
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationProfarma
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationProfarma
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 ResultsEmbraer RI
 
2Q 2011 Results Conference Call
2Q 2011 Results Conference Call 2Q 2011 Results Conference Call
2Q 2011 Results Conference Call WEG
 

Similaire à Profarma apresentação 2 q11 (19)

Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Eng
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
 
Earnings Release 2Q09 Presentation
Earnings Release 2Q09 PresentationEarnings Release 2Q09 Presentation
Earnings Release 2Q09 Presentation
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
arnings Release 2Q07 Presentation
arnings Release 2Q07 Presentationarnings Release 2Q07 Presentation
arnings Release 2Q07 Presentation
 
Earnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationEarnings Release 1Q07 Presentation
Earnings Release 1Q07 Presentation
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
 
Presentation CCR - 3Q09
Presentation CCR - 3Q09Presentation CCR - 3Q09
Presentation CCR - 3Q09
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results
 
Idea Cellular
Idea  CellularIdea  Cellular
Idea Cellular
 
2Q 2011 Results Conference Call
2Q 2011 Results Conference Call 2Q 2011 Results Conference Call
2Q 2011 Results Conference Call
 

Plus de Profarma

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17Profarma
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17Profarma
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17Profarma
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17Profarma
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17Profarma
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17Profarma
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 PresentationProfarma
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16Profarma
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejoProfarma
 
Teleconferência 2Q15
Teleconferência 2Q15Teleconferência 2Q15
Teleconferência 2Q15Profarma
 
Teleconferência 2T15
Teleconferência 2T15Teleconferência 2T15
Teleconferência 2T15Profarma
 

Plus de Profarma (20)

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 Presentation
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings release
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejo
 
1 q16
1 q161 q16
1 q16
 
4 t15
4 t154 t15
4 t15
 
4 q15
4 q154 q15
4 q15
 
3 q15
3 q153 q15
3 q15
 
3 t15
3 t153 t15
3 t15
 
Teleconferência 2Q15
Teleconferência 2Q15Teleconferência 2Q15
Teleconferência 2Q15
 
Teleconferência 2T15
Teleconferência 2T15Teleconferência 2T15
Teleconferência 2T15
 

Dernier

Q3 2024 Earnings Conference Call and Webcast Slides
Q3 2024 Earnings Conference Call and Webcast SlidesQ3 2024 Earnings Conference Call and Webcast Slides
Q3 2024 Earnings Conference Call and Webcast SlidesMarketing847413
 
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance BookingCall Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Bookingroncy bisnoi
 
The Economic History of the U.S. Lecture 18.pdf
The Economic History of the U.S. Lecture 18.pdfThe Economic History of the U.S. Lecture 18.pdf
The Economic History of the U.S. Lecture 18.pdfGale Pooley
 
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...shivangimorya083
 
Log your LOA pain with Pension Lab's brilliant campaign
Log your LOA pain with Pension Lab's brilliant campaignLog your LOA pain with Pension Lab's brilliant campaign
Log your LOA pain with Pension Lab's brilliant campaignHenry Tapper
 
Solution Manual for Financial Accounting, 11th Edition by Robert Libby, Patri...
Solution Manual for Financial Accounting, 11th Edition by Robert Libby, Patri...Solution Manual for Financial Accounting, 11th Edition by Robert Libby, Patri...
Solution Manual for Financial Accounting, 11th Edition by Robert Libby, Patri...ssifa0344
 
High Class Call Girls Nagpur Grishma Call 7001035870 Meet With Nagpur Escorts
High Class Call Girls Nagpur Grishma Call 7001035870 Meet With Nagpur EscortsHigh Class Call Girls Nagpur Grishma Call 7001035870 Meet With Nagpur Escorts
High Class Call Girls Nagpur Grishma Call 7001035870 Meet With Nagpur Escortsranjana rawat
 
Malad Call Girl in Services 9892124323 | ₹,4500 With Room Free Delivery
Malad Call Girl in Services  9892124323 | ₹,4500 With Room Free DeliveryMalad Call Girl in Services  9892124323 | ₹,4500 With Room Free Delivery
Malad Call Girl in Services 9892124323 | ₹,4500 With Room Free DeliveryPooja Nehwal
 
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptxFinTech Belgium
 
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130Suhani Kapoor
 
00_Main ppt_MeetupDORA&CyberSecurity.pptx
00_Main ppt_MeetupDORA&CyberSecurity.pptx00_Main ppt_MeetupDORA&CyberSecurity.pptx
00_Main ppt_MeetupDORA&CyberSecurity.pptxFinTech Belgium
 
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service NashikHigh Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service NashikCall Girls in Nagpur High Profile
 
The Economic History of the U.S. Lecture 21.pdf
The Economic History of the U.S. Lecture 21.pdfThe Economic History of the U.S. Lecture 21.pdf
The Economic History of the U.S. Lecture 21.pdfGale Pooley
 
20240417-Calibre-April-2024-Investor-Presentation.pdf
20240417-Calibre-April-2024-Investor-Presentation.pdf20240417-Calibre-April-2024-Investor-Presentation.pdf
20240417-Calibre-April-2024-Investor-Presentation.pdfAdnet Communications
 
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdfFinTech Belgium
 
Call US 📞 9892124323 ✅ Kurla Call Girls In Kurla ( Mumbai ) secure service
Call US 📞 9892124323 ✅ Kurla Call Girls In Kurla ( Mumbai ) secure serviceCall US 📞 9892124323 ✅ Kurla Call Girls In Kurla ( Mumbai ) secure service
Call US 📞 9892124323 ✅ Kurla Call Girls In Kurla ( Mumbai ) secure servicePooja Nehwal
 
Instant Issue Debit Cards - High School Spirit
Instant Issue Debit Cards - High School SpiritInstant Issue Debit Cards - High School Spirit
Instant Issue Debit Cards - High School Spiritegoetzinger
 
VIP Call Girls LB Nagar ( Hyderabad ) Phone 8250192130 | ₹5k To 25k With Room...
VIP Call Girls LB Nagar ( Hyderabad ) Phone 8250192130 | ₹5k To 25k With Room...VIP Call Girls LB Nagar ( Hyderabad ) Phone 8250192130 | ₹5k To 25k With Room...
VIP Call Girls LB Nagar ( Hyderabad ) Phone 8250192130 | ₹5k To 25k With Room...Suhani Kapoor
 
Quarter 4- Module 3 Principles of Marketing
Quarter 4- Module 3 Principles of MarketingQuarter 4- Module 3 Principles of Marketing
Quarter 4- Module 3 Principles of MarketingMaristelaRamos12
 

Dernier (20)

Q3 2024 Earnings Conference Call and Webcast Slides
Q3 2024 Earnings Conference Call and Webcast SlidesQ3 2024 Earnings Conference Call and Webcast Slides
Q3 2024 Earnings Conference Call and Webcast Slides
 
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance BookingCall Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Booking
 
The Economic History of the U.S. Lecture 18.pdf
The Economic History of the U.S. Lecture 18.pdfThe Economic History of the U.S. Lecture 18.pdf
The Economic History of the U.S. Lecture 18.pdf
 
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
 
Log your LOA pain with Pension Lab's brilliant campaign
Log your LOA pain with Pension Lab's brilliant campaignLog your LOA pain with Pension Lab's brilliant campaign
Log your LOA pain with Pension Lab's brilliant campaign
 
Solution Manual for Financial Accounting, 11th Edition by Robert Libby, Patri...
Solution Manual for Financial Accounting, 11th Edition by Robert Libby, Patri...Solution Manual for Financial Accounting, 11th Edition by Robert Libby, Patri...
Solution Manual for Financial Accounting, 11th Edition by Robert Libby, Patri...
 
High Class Call Girls Nagpur Grishma Call 7001035870 Meet With Nagpur Escorts
High Class Call Girls Nagpur Grishma Call 7001035870 Meet With Nagpur EscortsHigh Class Call Girls Nagpur Grishma Call 7001035870 Meet With Nagpur Escorts
High Class Call Girls Nagpur Grishma Call 7001035870 Meet With Nagpur Escorts
 
Malad Call Girl in Services 9892124323 | ₹,4500 With Room Free Delivery
Malad Call Girl in Services  9892124323 | ₹,4500 With Room Free DeliveryMalad Call Girl in Services  9892124323 | ₹,4500 With Room Free Delivery
Malad Call Girl in Services 9892124323 | ₹,4500 With Room Free Delivery
 
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
 
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
 
00_Main ppt_MeetupDORA&CyberSecurity.pptx
00_Main ppt_MeetupDORA&CyberSecurity.pptx00_Main ppt_MeetupDORA&CyberSecurity.pptx
00_Main ppt_MeetupDORA&CyberSecurity.pptx
 
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service NashikHigh Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
 
The Economic History of the U.S. Lecture 21.pdf
The Economic History of the U.S. Lecture 21.pdfThe Economic History of the U.S. Lecture 21.pdf
The Economic History of the U.S. Lecture 21.pdf
 
20240417-Calibre-April-2024-Investor-Presentation.pdf
20240417-Calibre-April-2024-Investor-Presentation.pdf20240417-Calibre-April-2024-Investor-Presentation.pdf
20240417-Calibre-April-2024-Investor-Presentation.pdf
 
Veritas Interim Report 1 January–31 March 2024
Veritas Interim Report 1 January–31 March 2024Veritas Interim Report 1 January–31 March 2024
Veritas Interim Report 1 January–31 March 2024
 
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
 
Call US 📞 9892124323 ✅ Kurla Call Girls In Kurla ( Mumbai ) secure service
Call US 📞 9892124323 ✅ Kurla Call Girls In Kurla ( Mumbai ) secure serviceCall US 📞 9892124323 ✅ Kurla Call Girls In Kurla ( Mumbai ) secure service
Call US 📞 9892124323 ✅ Kurla Call Girls In Kurla ( Mumbai ) secure service
 
Instant Issue Debit Cards - High School Spirit
Instant Issue Debit Cards - High School SpiritInstant Issue Debit Cards - High School Spirit
Instant Issue Debit Cards - High School Spirit
 
VIP Call Girls LB Nagar ( Hyderabad ) Phone 8250192130 | ₹5k To 25k With Room...
VIP Call Girls LB Nagar ( Hyderabad ) Phone 8250192130 | ₹5k To 25k With Room...VIP Call Girls LB Nagar ( Hyderabad ) Phone 8250192130 | ₹5k To 25k With Room...
VIP Call Girls LB Nagar ( Hyderabad ) Phone 8250192130 | ₹5k To 25k With Room...
 
Quarter 4- Module 3 Principles of Marketing
Quarter 4- Module 3 Principles of MarketingQuarter 4- Module 3 Principles of Marketing
Quarter 4- Module 3 Principles of Marketing
 

Profarma apresentação 2 q11

  • 1. 1
  • 2. 2Q11 Earnings Release August, 11th, 2011 2
  • 3. Highlights in the Period • Net income rose by 333.6% quarter-over-quarter and totaled R$ 9.5 million, with a 1.4% net margin; • Consolidated gross revenues grew 7.5% year-over-year, totaling R$ 779.4 million; • Highlight for the health and beauty category, whose sales increased for the sixth quarter in a row. There was a steep year- over-year increase of 87.3%; • The positive operating cash flow amounted to R$ 50.0 million in 2Q11, or 7.6% of the net operating revenue; • There was 5.8-day reduction in the cash cycle. This decrease resulted in a drop in working capital of about R$ 45.4 million; • Operating (administrative, selling and logistics) expenses fell by 1.4 percentage point year-over-year and totaled 7.5% of the net operating revenue; • Sales through electronic orders hit a record high and accounted for 68.6% of total sales in 2Q11. 3 3
  • 4. Gross Revenues Evolution (R$ Million) 778.8 779.4 724.7 2Q10 1Q11 2Q11 4 4
  • 5. Gross Revenues Breakdown (R$ Million) 2Q11 2Q10 Chg. % 1Q11 Chg. % Branded 512.2 477.5 7.3% 507.1 1.0% Generic 45.7 50.3 -9.1% 54.5 -16.1% OTC 141.3 143.8 -1.7% 148.7 -4.9% Health and Beauty Products 53.9 28.8 87.3% 47.6 13.1% Hospitals + Vaccines 26.3 24.3 7.9% 21.0 25.3% Total 779.4 724.7 7.5% 778.8 0.1% 5 5
  • 6. Market Share Evolution (%) 11.5 11.7 10.9* 10.2* 9.6 9.5* 9.9* 9.0* 2006 2007 2008 2009 2010 2Q10 1Q11 2Q11 *Excluding the similar’s effect Source: IMS and Profarma 6 6
  • 7. Gross Profit and Revenues from Services to Suppliers (R$ million and as % Net Revenues) 12.3% 10.7% 9.6% 25.1 27.4 24.0 49.7 39.1 42.9 2Q10 1Q11 2Q11 Gross Profit Revenues from Services to Suppliers Gross Profit Margin (%) 7 7
  • 8. Operating Expenses (R$ million and as % Net Revenues) 8.9% 7.7% 7.5% 53.8 50.7 49.5 2Q10 1Q11 2Q11 8 8
  • 9. Ebitda and Ebitda Margin (R$ million and as % Net Revenues) 3.6% 3.2% 1.7% 21.8 20.7 10.9 2Q10 1Q11 2Q11 9 9
  • 10. Net Financial Expenses (R$ million and as % Net Revenues) 1.9% 1.3% 1.1% 11.8 8.8 7.2 2Q10 1Q11 2Q11 10 10
  • 11. Net Profit (R$ million and as % Net Revenues) 1.9% 1.4% 0.3% 11.4 9.5 2.2 2Q10 1Q11 2Q11 11 11
  • 12. CASH FLOW (R$ Million) 2Q11 2Q10 Chg. % 1Q11 Chg. % Cash Flow Generated / (Used) in Operating Activities 50,0 46,8 6,9% (80,2) - Internal Cash Generation 19,8 17,6 12,7% 10,4 90,6% Operating Assets Variation 30,2 29,2 3,5% (90,6) - Trade Accounts Receivable 37,3 28,3 31,7% 22,9 62,6% Inventories 46,3 92,4 -50,0% (30,8) - Suppliers (48,7) (105,2) 53,7% (74,7) 34,8% Other Items (4,6) 13,7 - (8,1) 42,9% Cash Flow (Used) in Investing Activities (1,8) (1,9) 3,3% (1,3) -43,2% Cash Flow Generated / (Used) by Financing Activities (51,0) (53,7) 5,1% 81,1 - Net Increase / (Decrease) in Cash (2,8) (8,8) 68,5% (0,4) -659,2% 12 12
  • 13. Cycle IFRS Basis 2Q10 1Q11 2Q11 Cash Cycle (Days) * 66.3 64.5 60.4 Accounts Receivable (1) 42.2 43.9 39.4 Inventories (2) 48.8 59.3 53.1 Accounts Payable (3) 24.8 38.7 32.0 * Average (1) Average of Gross Revenues in the Quarter (2) Average of COGS in the Quarter (3) Average of COGS in the Quarter 13 13
  • 14. Indebtedness: Net Debt and Net Debt / Ebitda* (R$ million) 2.7x 2.2x 1.4x 194.8 157.1 132.5 2Q10 1Q11 2Q11 * Ebitda = Accumulated last 12 months 14 14
  • 15. Capex (R$ million and % as Net Revenues) 0.3% 0.2% 0.3% 1.9 1.9 1.3 2Q10 1Q11 2Q11 15 15
  • 16. Operating Indicators Service Level Logistics E.P.M. (Units served/ Units requested) (Errors per Million) 89.6% 89.5% 337.0 88.6% 144.0 121.0 2Q10 1Q11 2Q11 2Q10 1Q11 2Q11 16 16
  • 17. Profarma vs Ibovespa - % (2Q11) 115 110 105 100 97 95 91 90 85 31-Mar-11 15-Apr-11 30-Apr-11 15-May-11 30-May-11 14-Jun-11 29-Jun-11 Ibovespa Profarma 17 17
  • 18. Analyst Coverage Company Analyst Telephone E-mail Javier Martinez de Olcoz Cerdan (1 212) 761-4542 javier.martinez.olcoz@morganstanley.com Morgan Stanley Clarissa Berman (55 11) 3048-6214 clarissa.berman@morganstanley.com Merrill Lynch Alexandre Pizano (55 11) 2188-4024 alexandre.pizano@baml.com Credit Suisse Marcel Moraes (55 11) 3841-6302 marcel.moraes@credit-suisse.com Juliana Rozenbaum (55 11) 3073-3035 juliana.rozenbaum@itausecurities.com Itaú BBA Marcio Osako (55 11) 3073-3040 marcio.osako@itausecurities.com Banco Fator Iago Whately (55 11) 3049-9480 iwhately@bancofator.com.br Raymond James Guilherme Assis (55 11) 3513-8706 guilherme.assis@raymondjames.com BTG Pactual João Carlos dos Santos (55 11) 3383-2384 joaocarlos.santos@btgpactual.com 18 18
  • 19. 19